Market Herald Interview

In May, Imagion signed a collaboration agreement with Siemens Healthineers to explore the utility of our MagSense nanoparticles as a contrast agent in MRI…


Imagion Nanoparticle Manufacturing Update

Imagion Biosystems Limited is pleased to report that the first phase of manufacturing of the MagSense™ HER2 nanoparticle formulation under Good…


Imagion Biosystems Establishes Collaboration with Siemens Healthineers

Imagion Biosystems Limited announces it has entered into a collaboration agreement with Siemens Healthcare Pty Ltd of Australia (Siemens Healthineers) to…


Imagion Biosystems Nanoparticles Used in Viral Therapy Research

Imagion Biosystems Limited is pleased to share news of a recent publication, led by researchers at the Weill Cornell Medical College, which reports use of the…


Imagion Biosystems May 2020 Investor Newsletter

Imagion Biosystems Limited is pleased to provide investors with its May 2020 Investor Newsletter. The newsletter details recent key company developments and…


Initial Director's Interest Notice – Dianne Angus

Imagion Biosystems Limited has announced "Appendix 3X: Initial Director's Interest Notice." Read Appendix 3X.


Imagion Appoints New Non-Executive Director

Imagion Biosystems Limited today announced the appointment of Ms Dianne Angus to the Board of Directors. Ms Angus joined the Board as a Non-Executive Director…


Imagion Directors Take Up Entitlement in Rights Offers

Five Appendices 3Y, "Change of Director's Interest Notice", have been released to announce the entitlement right offers taken up by Imagion Directors. Read the…


Appendix 4G

Imagion Biosystems has released Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations. Read Appendix 4G


Annual Report to Shareholders

Imagion Biosystems has released its Annual Report to Shareholders for the year ended 31 December 2019. Read the Annual Report.